{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-004251","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2024-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.529018+00:00","generated_at":"2026-06-06T14:57:14.762831+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Processa Pharmaceuticals prices $7M public offering of 1.56M shares and warrants at $4.50 per unit","bullets":["Pricing of 1,555,555 shares (or pre-funded warrants) and common warrants at $4.50 per unit; gross proceeds ~$7M.","Common warrants exercisable at $4.50/share, immediately exercisable, 5-year term; pre-funded warrants at $0.0001.","H.C. Wainwright & Co. as sole placement agent with 7.0% cash fee and placement agent warrants.","Offering closed Jan 30, 2024; net proceeds for general corporate purposes.","90-day lock-up on equity issuance subject to exceptions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-004251","json":"https://secwatch.observer/filing/0001493152-24-004251.json","markdown":"https://secwatch.observer/filing/0001493152-24-004251.md","text":"https://secwatch.observer/filing/0001493152-24-004251.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224004251/0001493152-24-004251-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224004251/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T14:57:14.762831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f55ae0bb37327e0533cac87e102e3f00298ebc5","claim":"Processa Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $7.0 million (effective 2024-01-26).","evidence_excerpt":"On January 26, 2024, Processa Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell and issue, in a registered public offering (the “Offering”), (i) 476,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “common stock”), (ii) warrants to purchase 1,555,555 shares of common stock (the “Common Warrants”) and (iii) pre-funded warrants to purchase up to 1,079,555 shares of common stock in lieu of shares of common stock (the “Pre-Funded Warrants”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224004251/0001493152-24-004251-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"approximately $7.0 million"},{"label":"Effective","value":"2024-01-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}